Barclays Downgrades Enanta Pharmaceuticals (ENTA) to Underweight
Tweet
Share
E-mailGet Alerts ENTA Hot Sheet
Price: $13.47 +2.59%
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
15 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Barclays downgraded Enanta Pharmaceuticals (NASDAQ: ENTA) from Equalweight to Underweight with a price target of $16.00 (from $45.00).
For an analyst ratings summary and ratings history on Enanta Pharmaceuticals click here. For more ratings news on Enanta Pharmaceuticals click here.
Shares of Enanta Pharmaceuticals closed at $23.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stella International Holdings (1836:HK) (SLNLF) PT Lowered to HK$10 at Macquarie
- Cummins (CMI) PT Lowered to $675 at Jefferies
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
